CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,681 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01079182
NCT01079182N/ACompleted
CompareCT.gov

Safety and Effectiveness of Adalimumab in Patients With Ankylosing Spondylitis in Routine Clinical Practice

AbbVie (prior sponsor, Abbott)·observational·Posted Mar 3, 2010·Updated Jul 9, 2015

In Brief

An observational study for Ankylosing Spondylitis. Completed, enrolled 4,681 participants.

Detailed Summary

The research question explored in this study was whether the effectiveness and safety of adalimumab in participants with ankylosing spondylitis was maintained during long-term therapy in routine clinical practice in Germany.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 3, 2010
Enrollment StartJan 1, 2006
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 16.3 years ago